DeepCure developed an AI platform designed to search the enormous chemical space with high accuracy. By combining the power of its deep learning algorithms, cloud computing infrastructure, and proprietary database of 1 trillion chemistries, DeepCure's platform finds drug candidates that deliver improved value to patients.
DeepCure's proprietary molecular database, MolDB, is a large medicinal chemistry database that covers over 1 trillion compounds and is expanded on demand to 1 quintillion molecules. These compounds are highly diverse and span most of the chemical space currently accessible to chemists. The trillion compounds cover more than 75% of existing medicinal chemistry compounds, including drugs and current clinical candidates in development, synthesized, or reported by medicinal chemists.
In addition, a suite of generative models can expand each selected molecule to a million analogs, expanding the search even further to 1 quintillion (10^18) molecules.
MolDB enables the discovery of candidates that don't exist in traditional screening libraries.
Cumulative Funding Raised Over Time ($)
Employees Over Time
DeepCure Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jan 4, 2023
www.businesswire.com
Biosero and DeepCure Collaborate to Establish Fully Automated, AI-Powered Chemistry Synthesis Platform
undefined
Apr 26, 2022
www.businesswire.com
DeepCure Appoints Dr. Han Lim as Chief Business Officer
undefined
Nov 8, 2021
www.businesswire.com
DeepCure Closes $40M Series A Funding Led by Morningside Ventures